An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.

Trial Profile

An Observational Registration Study of Infusion-related Adverse Events at Administration of Mabthera (Rituximab) in the Treatment of Chronic Lymphocytic Leukemia.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Nov 2015

At a glance

  • Drugs Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational
  • Sponsors Roche
  • Most Recent Events

    • 18 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Jul 2011 Planned end date changed from Dec 2010 to Dec 2012 as reported by ClinicalTrials.gov.
    • 26 May 2010 Status changed from not yet recruiting to recruiting as reported by Roche website..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top